After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy for the condition. More: FDA greenlights Stealth Bio’s injection as 1st
read moreIn the second and final day of the CDC’s Advisory Committee on Immunization Practices September meeting, members of the panel scrapped one vote, reversed another and stopped just short of endorsing a third that had the potential to significantly impede
read moreThe FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s best-selling drug potential blockbuster revenue protection. More: Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection Source:
read moreTakeda employees from around the world climbed Mount Fuji, a challenge that was meant not only to represent and celebrate the recent rollout of several of the company’s PDTs in Japan but also to raise awareness of PDTs and the
read moreThe CDC’s recommendation for Gilead’s twice-yearly Yeztugo as an HIV PrEP option was hailed by HIV advocacy groups but stirred up pressure for CVS Health to include the drug on its formularies. More: CDC 'strongly' backs Gilead's HIV PrEP Yeztugo,
read moreEurope’s Committee for Medicinal Products for Human Use (CHMP) has recommended several drugs for approval, including Novo Nordisk’s once-weekly diabetes drug Kyinsu and Bayer’s menopause treatment Lynkuet. More: Novo's once-weekly combo drug for Type 2 diabetes scores EU endorsement Source:
read more© 1994 - 2026 B.M. Pharmaceuticals